Who owns the cord?

My focus here is not on the immense value of cord blood cells in regenerative medicine but one central ethical issue surrounding the revolutionary science. Whether posthumous or not, the informed consent in issue donation is always a hazy area that is not easy to be governed under regulation. This is because we can’t conclude in legal terms as to who’s the real donor: the mother or her child?

Today, most of the procurement happens only after due consent but the larger question still remains: can this consent be deemed adequate and full-proof in law?  In today’s fast-paced times of invariably strained familial relations, one can’t rule out the possibility of a disputing claim made by a member overriding the mother’s consent. Imagine the complexities it could invite at the door of the clinic long after the donation has been made and utilized for good.

The million dollar (unanswered) question is: who owns the cord? The law is undecided – at times, it assumes the placenta or umbilicus to be part of the mother and in some cases, part of the child. The Genetic argument does favour the child but can’t rule out the claim of family including the father and siblings – both living and future. The logical way out is to make the consent process as inclusive as possible. Which means, rather than assuming things, one should seek the consent of both parents on behalf of their child.

But this is easier said than done. Property rights in human tissue are an unexplored area – both from the judicial and the more important ethical point of view. It’s clearly a long-drawn process of introspection and deliberation and we certainly can’t expect a silver bullet in the form of a solution.

The best we can do NOW is to trigger a global public discussion across all forums – medical or otherwise – on this critical issue that could one day truly unlock the phenomenal potential of this therapeutic stream.

Supply side Stem Cell Universe: EPC Value Prop

Whether therapeutic or research centric, the stem cell space can prove baffling, more so for a prospective entrant. Our 3D Approach (DEFINE-DESIGN-DEPLOY) has been specifically designed to help stem cell players move up the value chain in line with their scale and scope frameworks.Whether new entrants, VCs, entities from allied industries or existing players, we can help you with a tailored roadmap to tap opportunities, decipher technical intricacies, address regulatory approvals, build commensurate infrastructure, offer comprehensive services, create competitive edge and eventually capture better market share.
These are Incubation services for new entrants especially on market research, adoption of proven, validated stem cell lines, government and regulatory approvals, third party validations and legal certifications.
 These are blueprint services for state-of-the-art lab design, environmental control, quality control, cryopreservation technologies, procurement, validation & installation of equipment and tools, supply of consumables and infrastructure optimization in line with global best practices.
These are niche services including technical and scientific support, clinical facilitation, headhunting, operational management, value chain development, branding, PR and stakeholder communication, business development, product marketing and vale added content development spanning web, electronic and print media.
In addition, you can count on EPC Advisory for:
Patented and proven clinical expertise
Core Value chain of hospitals, clinics, doctors & researchers
Structured cost and service models
Accreditation of hospitals and clinics
Strategic business development
International campaigns, seminars and exhibitions
Streamlining immigration process for medical tourists
Creation of quality convalescence hubs